Clinical outcome of patients with inoperable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus Nab‑paclitaxel as a first‑line therapy: A retrospective analysis

Sakaguchi,Hiroyuki; Tanimoto,Azusa; Sato,Shigeki; Yanagimura,Naohiro; Suzuki,Chiaki; Takumi,Yohei; Nishiyama,Akihiro; Yamashita,Kaname; Takeuchi,Shinji; Ohtsubo,Koshiro; Yano,Seiji

doi:10.3892/mi.2021.8

Clinical outcome of patients with inoperable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus Nab‑paclitaxel as a first‑line therapy: A retrospective analysis

Authors:
- Hiroyuki Sakaguchi
- Azusa Tanimoto
- Shigeki Sato
- Naohiro Yanagimura
- Chiaki Suzuki
- Yohei Takumi
- Akihiro Nishiyama
- Kaname Yamashita
- Shinji Takeuchi
- Koshiro Ohtsubo
- Seiji Yano
View Affiliations

Affiliations: Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa 920‑0934, Japan
Published online on: July 5, 2021 https://doi.org/10.3892/mi.2021.8
Article Number: 8
Copyright : © Sakaguchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the clinical benefits of leucovorin, 5‑fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) vs. gemcitabine plus Nab‑paclitaxel (GnP) as a first‑line therapy for patients with inoperable pancreatic cancer. For this purpose, in‑house data available for 45 patients who received FOLFIRINOX or GnP as first‑line treatment between 2014 and 2019 were retrospectively analyzed. In total, 21 and 24 patients received FOLFIRINOX and GnP, respectively. Although there were no significant differences in the median progression‑free survival, the median overall survival was longer in the FOLFIRINOX group than in the GnP group (16.7 vs. 7.2 months). A total of 14 patients received FOLFIRINOX followed by GnP, whereas 3 patients received GnP followed by FOLFIRINOX. All patients who did not switch to second‑line therapy owing to poor feasibility were included in the GnP group. The data indicated that patients receiving GnP as first‑line therapy were less likely to switch to FOLFIRINOX and, consequently, had a worse prognosis.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.PubMed/NCBI View Article : Google Scholar
2	Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA. 297:267–277. 2007.PubMed/NCBI View Article : Google Scholar
3	Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et al: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 381:317–327. 2019.PubMed/NCBI View Article : Google Scholar
4	Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, et al: trial investigators: Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials. Lancet Oncol. 21:271–282. 2020.PubMed/NCBI View Article : Google Scholar
5	Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.PubMed/NCBI View Article : Google Scholar
6	Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013.PubMed/NCBI View Article : Google Scholar
7	Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, et al: NAPOLI-1 Study Group: Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial. Lancet. 387:545–557. 2016.PubMed/NCBI View Article : Google Scholar
8	Williet N, Saint A, Pointet AL, Tougeron D, Pernot S, Pozet A, Bechade D, Trouilloud I, Lourenco N, Hautefeuille V, et al: Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: A comparative propensity score study. Therap Adv Gastroenterol. 12(1756284819878660)2019.PubMed/NCBI View Article : Google Scholar
9	Matsumoto T, Kurioka Y, Okazaki U, Matsuo Y, Kimura S, Miura K, Tsuduki T, Takagi S, Takatani M and Morishita H: FOLFIRINOX for advanced pancreatic cancer patients after Nab-paclitaxel plus gemcitabine failure. Pancreas. 49:574–578. 2020.PubMed/NCBI View Article : Google Scholar
10	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.PubMed/NCBI View Article : Google Scholar
11	Lee JC, Woo SM, Shin DW, Kim J, Yang SY, Kim MJ, Kim JW, Kim JW, Lee WJ, Cha HS, et al: Comparison of FOLFIRINOX and gemcitabine plus Nab-paclitaxel for treatment of metastatic pancreatic cancer: using Korean pancreatic cancer (K-PaC) registry. Am J Clin Oncol. 43:654–659. 2020.PubMed/NCBI View Article : Google Scholar
12	Vogl UM, Andalibi H, Klaus A, Vormittag L, Schima W, Heinrich B, Kafka A, Winkler T and Öhler L: Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: Does sequence matter? BMC Cancer. 19(28)2019.PubMed/NCBI View Article : Google Scholar
13	Pusceddu S, Ghidini M, Torchio M, Corti F, Tomasello G, Niger M, Prinzi N, Nichetti F, Coinu A, Di Bartolomeo M, et al: Comparative effectiveness of gemcitabine plus Nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis. Cancers (Basel). 11(E484)2019.PubMed/NCBI View Article : Google Scholar
14	Itoh T, Takemoto I, Itagaki S, Sasaki K, Hirano T and Iseki K: Biliary excretion of irinotecan and its metabolites. J Pharm Pharm Sci. 7:13–18. 2004.PubMed/NCBI
15	Kang J, Lee SH, Choi JH, Paik WH, Ahn DW, Jeong JB, Ryu JK and Kim YT: Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancreatic cancer. Hepatobiliary Pancreat Dis Int. 19:590–595. 2020.PubMed/NCBI View Article : Google Scholar
16	Bonnet E, Mastier C, Lardy-Cléaud A, Rochefort P, Sarabi M, Guibert P, Cattey-Javouhey A, Desseigne F and de La Fouchardière C: FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: A retrospective study. Curr Oncol. 26:e466–e472. 2019.PubMed/NCBI View Article : Google Scholar
17	Kinoshita J, Fushida S, Tsukada T, Oyama K, Watanabe T, Shoji M, Okamoto K, Nakanuma S, Sakai S, Makino I, et al: Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer. Oncol Rep. 32:89–96. 2014.PubMed/NCBI View Article : Google Scholar
18	Kondo T, Kanai M, Kou T, Sakuma T, Mochizuki H, Kamada M, Nakatsui M, Uza N, Kodama Y, Masui T, et al: Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Oncotarget. 9:19817–19825. 2018.PubMed/NCBI View Article : Google Scholar
19	Peixoto RD, Ho M, Renouf DJ, Lim HJ, Gill S, Ruan JY and Cheung WY: Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX. Am J Clin Oncol. 40:507–511. 2017.PubMed/NCBI View Article : Google Scholar